There were 1,761 press releases posted in the last 24 hours and 359,282 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image